


AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application:

1. (Currently Amended) A method for treating the negative symptoms of schizophrenia and/or the cognitive dysfunction of schizophrenia in a patient, ~~without said treatment being accompanied by any extrapyramidal symptoms~~, which comprises orally administering a once daily dose of 5 mg to 120 mg of the active compound: (1R,2S,3R,4S)-N-[(1R,2R)-2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinylmethyl]-1-cyclohexylmethyl]-2,3-bicyclo[2.2.1]heptanedicarboxyimide of the formula (1):



or a pharmaceutically acceptable salt thereof to a patient suffering from negative symptoms of schizophrenia and/or cognitive dysfunction of schizophrenia.

2. (Previously presented) The method of claim 1, 22 or 23 wherein the pharmaceutically acceptable salt of said active compound is (1R,2S,3R,4S)-N-[(1R,2R)-2-[4-(1,2benzothiazol-3-yl)-1-piperazinylmethyl]-1-cyclohexylmethyl]-2,3-bicyclo[2.2.1]heptanedicarboxyimide hydrochloride.

3. - 4. (Canceled)

5. (Currently amended) The method of any one of claims 1, 2, 22 and 23, wherein a once daily dose of 20 mg to 80 mg of said active compound or a pharmaceutically acceptable salt thereof is administered to said patient.

6. - 7. (Canceled)

8. (Currently Amended) The method of any one of claims 1, 2, 22 and 23, wherein said patient is in a chronic stage of schizophrenia, and wherein a once daily dose of 20 mg to 80 mg of said active compound or a pharmaceutically acceptable salt thereof is administered to said patient.

9. - 10. (Canceled)

11. (Currently Amended) The method of claim 8, wherein a once daily dose of 50 mg to 80 mg of said active compound or a pharmaceutically acceptable salt thereof is administered to said patient.

12. - 21. (Canceled)

22. (Previously presented) The method of claim 1, which is a method for treating the negative symptoms of schizophrenia in a patient.

23. (Previously presented) The method of claim 1, which is a method for treating the cognitive dysfunction of schizophrenia in a patient.

24. (New) The method of any one of claims 1, 2, 22 and 23, wherein said patient is in an acute stage of schizophrenia, and wherein a once daily dose of 40 mg to 120 mg of said active compound or a pharmaceutically acceptable salt thereof is administered to said patient.

25. (New) The method of any one of claims 1, 2, 22 and 23, wherein a once daily dose of 40 mg of said active compound or a pharmaceutically acceptable salt thereof is administered to said patient.

26. (New) The method of any one of claims 1, 2, 22 and 23, wherein a once daily dose of 80 mg of said active compound or a pharmaceutically acceptable salt thereof is administered to said patient.

27. (New) The method of any one of claims 1, 2, 22 and 23, wherein a once daily dose of 120 mg of said active compound or a pharmaceutically acceptable salt thereof is administered to said patient.